Lesovir-C is a fixed-dose combination tablet containing ledipasvir and sofosbuvir for oral administration. Ledipasvir is an HCV NS5A inhibitor and sofosbuvir is a nucleotide analog inhibitor of HCV NS5B polymerase. Each tablet contains 90 mg ledipasvir and 400 mg sofosbuvir.
Ledipasvir is an inhibitor of the HCV NS5A protein, which is required for viral replication. Resistance selection in cell culture and cross-resistance studies indicate ledipasvir targets NS5A as its mode of action.
Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator.
The development of ledipasvir and sofosbuvir fixed-dose combination eliminates the necessity of using Peginterferon-α and Ribavirin in the treatment of Chronic Hepatitis C Genotype 1 & 4.
Lesovir-C of Beximco Pharma is manufactured with novel solid-solid dispersion technology for the 1st time in Bangladesh. This technology is used for converting crystalline Ledipasvir to amorphous form as ledipasvir and sofosbuvir fixed-dose combination becomes more effective with the amorphous form. This solid-solid dispersion technology ensures
- Faster dissolution than crystalline form of Ledipasvir
- Improved bioavailability
- No food-drug interaction
- Similar treatment outcome across patient population
This solid-solid dispersion technology of Ledipasvir ensures faster dissolution rate compared to crystalline form.
Lesovir-C provides excellent clinical outcomes in Chronic Hepatitis Genotype 1 & 4 and has numerous benefits:
- More affordable and compliant than Interferon & Ribavirin based therapy
- Better tolerability profile than Interferon & Ribavirin based therapy
- USFDA pregnancy category B
Full Prescribing Information